CECEP Screens Two Monoclonal Antibodies That May Help to Identify Novel Coronavirus' Recombinant Protein

CECEP Valiant Co., Ltd, a subsidiary of China Energy Conservation and Environmental Protection Group (CECEP), has successfully screened two monoclonal antibodies that are expected to recognize the recombinant protein of the novel coronavirus, thanks to the efforts of a research and development team of 15 people who worked for 18 days straight.

Examination and production of the first antibody have now been completed.

As a professional medical and health enterprise under CECEP, Valiant decided to share that antibody with the scientific researchers who are fighting to improve the efficiency of research and development and advance prevention and control.

That monoclonal antibody has subsequently been verified to have the specific antigen binding ability of the novel coronavirus at the scientific research stage.

It is expected to be applied to the production of novel coronavirus antigen detection reagents and the research and development of vaccine and antibody drugs to be used against the epidemic.

(Executive editor: Wang Ruoting)